33.49
+0.51(+1.55%)
Currency In USD
| Previous Close | 32.98 |
| Open | 33.08 |
| Day High | 34.2 |
| Day Low | 32.66 |
| 52-Week High | 41.04 |
| 52-Week Low | 21.62 |
| Volume | 1.12M |
| Average Volume | 2.52M |
| Market Cap | 6.33B |
| PE | -13.84 |
| EPS | -2.42 |
| Moving Average 50 Days | 29.64 |
| Moving Average 200 Days | 27.12 |
| Change | 0.51 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,215.61 as of February 05, 2025 at a share price of $33.49. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $956.86 as of February 05, 2025 at a share price of $33.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
GlobeNewswire Inc.
Jan 13, 2025 4:00 PM GMT
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three major market Phase 3 clinical trials: FORTIFY (BB
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 12:30 PM GMT
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GlobeNewswire Inc.
Dec 13, 2024 12:18 PM GMT
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent with the CHMP recommendation,